期刊文献+

吉西他滨联合奥沙利铂治疗晚期复发转移卵巢癌的临床观察 被引量:2

The clinical observation of Gemcitabine and oxaliplatin in relapse and metastasis ovarian cancer
下载PDF
导出
摘要 目的探讨吉西他滨联合奥沙利铂治疗晚期复发转移卵巢癌的疗效及不良反应。方法本组21例患者给予吉西他滨和奥沙利铂治疗,连用2个周期后进行影像学检查、CA125评价疗效和观察不良反应。结果总有效率38.1%,恶心呕吐发生率17例(80.9%),神经毒性、感觉异常占13例(61.9%),白细胞下降15例(71.4%);血小板下降13例(61.9%);红细胞下降9例(42.9%)。结论吉西他滨联合奥沙利铂治疗晚期复发转移卵巢癌患者疗效确切,毒性反应低,耐受好,生存质量明显提高。 Objective To research the effectiveness and adverse reaction of gemcitabine and oxaliplatin in relapse and metastasis ovarian cancer.Methods A total of 21 patients in the group were trated with gemcitabine and t oxaliplatin,after two cycle,they rpeated imaging、CA125 and researched effectiveness and adverse reaction.Results The total cure rates of these drugs was 38.1%,nausea and vomiting incidence was 17 patients(80.9%),neurotoxicity and cacesthesia was 13 patients(61.9%),leucocyte decline was 15 patients(71.4%),blood cell decline was 13 patients(61.9%),red blood cell decline was 9 patients(42.9%).Conclusion Gemcitabine and oxaliplatin treated relapse and metastasis ovarian cancer had good effectiveness and low toxicity,the tolerance was good and quality of life was improved.
出处 《四川医学》 CAS 2012年第2期219-220,共2页 Sichuan Medical Journal
关键词 复发卵巢肿瘤 吉西他滨 奥沙利铂 联合化疗 relapse and metastasis ovarian cancer egemcitabine oxaliplatin
  • 相关文献

参考文献6

  • 1Shah MA.Ramanathan RK,Iison DH,et al.Muhicenter phase II studyof irinotecan。cisplatin,andbevacizumab in patients with metastaticgastric or gastroesophageal junction adenocarcinoma[J].J Clin Oncol,2006,24(33):5201~5206
  • 2茅卫东,邓立春,刘少平,王琼,袁明,林峰.吉西他滨联合顺铂治疗蒽环类耐药的晚期乳腺癌22例临床观察[J].实用临床医药杂志,2007,11(6):65-65. 被引量:6
  • 3周兆飞,陆建伟,尹必俭,刘德林,冯继锋,朱梁军,潘良熹.奥沙利铂联合5-氟脲嘧啶、甲酰四氢叶酸时辰治疗晚期胃肠道癌的临床研究[J].实用临床医药杂志,2007,11(2):16-18. 被引量:9
  • 4Faivre S,Raymond E,Woynaro W,et al.Supraadditive effect of 2.2-difluoxodeoxycytidine(gemcitabine)in com.bination with oxaliplatinin human cancer cell lines[J].Cancer Chemother Pharmacol,1999,44:117~123
  • 5Kalykaki A,Papakotoulas P,Tsousis S,et al.Gemcitabine plus oxali-platin(GEMOX)in pretreated patients with advanced ovarian cancel“:a muhicenter phase II study of the Hellenic Oncology Research Group(HORG)[J].Anticancer Research,2008,28:495~500
  • 6Pfisterer J,Plante M,Vergote I,et al.Gemcitabine/carboplatin(GC)vs carboplatin(C)in platinum sensitive recurrent ovariancancer(OVCA):results of a Gynecologic Cancer Intergroup randomized phaseⅢtrial of the AGO OVAR,the NCIC CTG and the EORTC GCG[J].Proc Am Soc Clin Oncol,2004,449:5005

二级参考文献24

共引文献12

同被引文献8

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部